MMSI · Company research
Merit Medical Systems Inc (MMSI): Stock News & Events
Recent company-linked news records available in the database.
RESEARCH CONTEXT
Understand the numbers
Recent company-linked news records available in the database. Use period, currency, units and source fields when interpreting values.
49records availableHealthcare
Stock News & Events data
Database-backed records only
| title | summary | url | source | published at | sentiment | sentiment score | relevance score |
|---|---|---|---|---|---|---|---|
| BD's Revello Stent Shows Strong AGILITY Trial Results for PAD Patients | Becton, Dickinson and Company (BD) announced positive nine-month results from the AGILITY trial for its Revello Vascular Covered Stent in treating iliac artery disease. The trial met its primary endpoint with a 2.8% failure rate, 97.2% primary patency, and 98.3% freedom from clinically driven target lesion revascularization. The device remains investigational in the U.S. with clinical follow-up continuing through 36 months. The global iliac stent market is projected to grow at a 6.5% CAGR through 2033. | View source ↗ | Zacks Investment Research | Oct 15, 2026 | bullish | 1 | 1 |
| BD's Revello Stent Shows Strong AGILITY Trial Results for PAD Patients | Becton, Dickinson and Company (BD) announced positive nine-month results from the AGILITY trial for its Revello Vascular Covered Stent in treating iliac artery disease. The trial met its primary endpoint with a 2.8% failure rate, 97.2% primary patency, and 98.3% freedom from clinically driven target lesion revascularization. The device remains investigational in the U.S. with clinical follow-up continuing through 36 months. The global iliac stent market is projected to grow at a 6.5% CAGR through 2033. | View source ↗ | Zacks Investment Research | Oct 15, 2026 | bullish | 1 | 1 |
| Doximity Deepens U.S. News Alliance to Improve Patient Access to Care | Doximity announced an extension of its 13-year partnership with U.S. News & World Report, continuing to provide physician data for Doctor Finder, Patient Connect appointment-booking tools, and Expert Opinion surveys for hospital rankings. The partnership leverages Doximity's network of 3+ million medical professionals to connect patients with healthcare providers. Despite the news, DOCS stock declined 2.1% following the announcement and is down 32.4% year-to-date. | View source ↗ | Zacks Investment Research | Oct 15, 2026 | bullish | 0.75 | 1 |
| Doximity Deepens U.S. News Alliance to Improve Patient Access to Care | Doximity announced an extension of its 13-year partnership with U.S. News & World Report, continuing to provide physician data for Doctor Finder, Patient Connect appointment-booking tools, and Expert Opinion surveys for hospital rankings. The partnership leverages Doximity's network of 3+ million medical professionals to connect patients with healthcare providers. Despite the news, DOCS stock declined 2.1% following the announcement and is down 32.4% year-to-date. | View source ↗ | Zacks Investment Research | Oct 15, 2026 | bullish | 0.75 | 1 |
| Merit Medical Systems, Inc. (MMSI) Stock Forecasts - Yahoo Finance | Merit Medical Systems, Inc. (MMSI) Stock Forecasts Yahoo Finance | View source ↗ | Yahoo Finance | Oct 15, 2026 | neutral | 0 | 0.6 |
| Glaukos Stock Gains 36.8% in 6 Months: What's Behind the Rally? | Glaukos Corporation (GKOS) shares have gained 36.8% over six months, outperforming its industry, driven by strong Q2 results with 50% revenue growth to $185.6 million, successful commercial expansion of Epioxa for keratoconus treatment, positive clinical data for iDose TR, and pipeline advances including a new retinal disease licensing agreement. The company raised its 2026 revenue guidance to $680-$700 million. | View source ↗ | Zacks Investment Research | Oct 14, 2026 | bullish | 1 | 1 |
| BTSG Stock Climbs 67.3% YTD: What's Driving the Rally in 2026? | BrightSpring Health Services (BTSG) has surged 67.3% year-to-date, outperforming broader markets, driven by strong growth in Specialty and Infusion revenues (up 32.7%) and Provider Services (up 29.1%). The company raised its 2026 outlook twice and improved leverage to 2.15x after divesting its Community Living business. However, a $200M IRA impact on Home and Community Pharmacy and integration execution risks present headwinds. Analysts rate BTSG as a Hold. | View source ↗ | Zacks Investment Research | Oct 14, 2026 | bullish | 1 | 1 |
| BTSG Stock Climbs 67.3% YTD: What's Driving the Rally in 2026? | BrightSpring Health Services (BTSG) has surged 67.3% year-to-date, outperforming broader markets, driven by strong growth in Specialty and Infusion revenues (up 32.7%) and Provider Services (up 29.1%). The company raised its 2026 outlook twice and improved leverage to 2.15x after divesting its Community Living business. However, a $200M IRA impact on Home and Community Pharmacy and integration execution risks present headwinds. Analysts rate BTSG as a Hold. | View source ↗ | Zacks Investment Research | Oct 14, 2026 | bullish | 1 | 1 |
| Reasons to Add QuidelOrtho Stock to Your Portfolio for Now | QuidelOrtho Corporation (QDEL) shows strong Q2 2026 results with 21% adjusted EBITDA growth and expanding margins, supported by a diversified product portfolio and $50 million cost-saving initiatives through 2027. However, weak respiratory demand and overdependence on this segment pose risks, with the company adopting a cautious outlook for the 2026-2027 respiratory season. | View source ↗ | Zacks Investment Research | Oct 14, 2026 | bullish | 1 | 1 |
| Reasons to Add QuidelOrtho Stock to Your Portfolio for Now | QuidelOrtho Corporation (QDEL) shows strong Q2 2026 results with 21% adjusted EBITDA growth and expanding margins, supported by a diversified product portfolio and $50 million cost-saving initiatives through 2027. However, weak respiratory demand and overdependence on this segment pose risks, with the company adopting a cautious outlook for the 2026-2027 respiratory season. | View source ↗ | Zacks Investment Research | Oct 14, 2026 | bullish | 1 | 1 |
| Hims & Hers Expands Australian Women's Health Platform With Hers | Hims & Hers Health has launched Hers, its women's health platform, in Australia by rebranding Juniper from its Eucalyptus acquisition. The platform offers personalized care for hair regrowth, menopause, and weight management with 24/7 support. The expansion leverages Eucalyptus' local presence to strengthen brand recognition and recurring revenue in the growing Australian telehealth market, which is projected to grow at 18.2% CAGR through 2034. | View source ↗ | Zacks Investment Research | Oct 14, 2026 | bullish | 0.75 | 1 |
| Hims & Hers Expands Australian Women's Health Platform With Hers | Hims & Hers Health has launched Hers, its women's health platform, in Australia by rebranding Juniper from its Eucalyptus acquisition. The platform offers personalized care for hair regrowth, menopause, and weight management with 24/7 support. The expansion leverages Eucalyptus' local presence to strengthen brand recognition and recurring revenue in the growing Australian telehealth market, which is projected to grow at 18.2% CAGR through 2034. | View source ↗ | Zacks Investment Research | Oct 14, 2026 | bullish | 0.75 | 1 |
| Here's Why You Should Add Avantor Stock to Your Portfolio for Now | Avantor (AVTR) reported strong second-quarter 2026 results with raised 2026 guidance, driven by VWR segment's return to 1.7% organic growth and BMP's double-digit order growth. However, BMP's continued 5.6% organic revenue decline and uneven demand recovery remain concerns. The company's Revival program shows execution improvements across commercial performance and operations. | View source ↗ | Zacks Investment Research | Oct 13, 2026 | bullish | 1 | 1 |
| Here's Why You Should Add Avantor Stock to Your Portfolio for Now | Avantor (AVTR) reported strong second-quarter 2026 results with raised 2026 guidance, driven by VWR segment's return to 1.7% organic growth and BMP's double-digit order growth. However, BMP's continued 5.6% organic revenue decline and uneven demand recovery remain concerns. The company's Revival program shows execution improvements across commercial performance and operations. | View source ↗ | Zacks Investment Research | Oct 13, 2026 | bullish | 1 | 1 |
| Here's Why You Should Retain AMN Stock in Your Portfolio for Now | AMN Healthcare is positioned for growth driven by rising healthcare staffing demand, technology investments, and higher-margin services, with Nurse and Allied revenues up 11% and Passport users growing 33%. However, persistent pricing competition, weakness in physician and technology segments, and earnings normalization pose significant headwinds to sustained performance. | View source ↗ | Zacks Investment Research | Oct 12, 2026 | bullish | 0.75 | 1 |
| Merit Medical Systems, Inc. (MMSI) Stock forecasts - Yahoo Finance UK | Merit Medical Systems, Inc. (MMSI) Stock forecasts Yahoo Finance UK | View source ↗ | Yahoo Finance UK | Oct 10, 2026 | neutral | 0 | 0.6 |
| Merit Medical Systems (MMSI) Rallies On Margin Progress, Is The Stock Still Cheap? - Yahoo Finance | Merit Medical Systems (MMSI) Rallies On Margin Progress, Is The Stock Still Cheap? Yahoo Finance | View source ↗ | Yahoo Finance | Oct 10, 2026 | neutral | 0 | 0.6 |
| Merit Medical Systems (MMSI) Stock Looks Cheap Based On Cash Flow - Yahoo Finance | Merit Medical Systems (MMSI) Stock Looks Cheap Based On Cash Flow Yahoo Finance | View source ↗ | Yahoo Finance | Oct 10, 2026 | neutral | 0 | 0.6 |
| Cancer Stocks to Consider as Oncology Innovation Accelerates | The global oncology market is experiencing rapid growth due to rising cancer incidence, aging populations, and medical advances including immunotherapies, targeted medicines, and personalized vaccines. Major pharmaceutical companies are investing heavily in oncology R&D, with innovations in antibody-drug conjugates, bispecific antibodies, and next-generation immunotherapies. Three companies highlighted for oncology exposure are Pfizer, Merit Medical Systems, and Abbott Laboratories. | View source ↗ | Zacks Investment Research | Oct 9, 2026 | bullish | 1 | 1 |
| Cancer Stocks to Consider as Oncology Innovation Accelerates | The global oncology market is experiencing rapid growth due to rising cancer incidence, aging populations, and medical advances including immunotherapies, targeted medicines, and personalized vaccines. Major pharmaceutical companies are investing heavily in oncology R&D, with innovations in antibody-drug conjugates, bispecific antibodies, and next-generation immunotherapies. Three companies highlighted for oncology exposure are Pfizer, Merit Medical Systems, and Abbott Laboratories. | View source ↗ | Zacks Investment Research | Oct 9, 2026 | bullish | 1 | 1 |
| Here's Why You Should Retain DaVita Stock in Your Portfolio for Now | DaVita (DVA) has rallied 55.8% year-to-date, driven by strong Integrated Kidney Care (IKC) platform growth, improving treatment volumes, and technology investments. The company beat Q2 expectations by $40 million in adjusted operating income and raised full-year guidance. However, persistent headwinds include declining revenue per treatment due to commercial-mix pressure (estimated $70 million impact in 2027), elevated G&A costs limiting operating leverage, and limited acquisition opportunities in a consolidated market. | View source ↗ | Zacks Investment Research | Oct 9, 2026 | bullish | 0.25 | 1 |
| Here's Why You Should Retain DaVita Stock in Your Portfolio for Now | DaVita (DVA) has rallied 55.8% year-to-date, driven by strong Integrated Kidney Care (IKC) platform growth, improving treatment volumes, and technology investments. The company beat Q2 expectations by $40 million in adjusted operating income and raised full-year guidance. However, persistent headwinds include declining revenue per treatment due to commercial-mix pressure (estimated $70 million impact in 2027), elevated G&A costs limiting operating leverage, and limited acquisition opportunities in a consolidated market. | View source ↗ | Zacks Investment Research | Oct 9, 2026 | bullish | 0.25 | 1 |
| Irenic Capital Management LP's Merit Medical Systems Inc(MMSI) Holding History - GuruFocus | Irenic Capital Management LP's Merit Medical Systems Inc(MMSI) Holding History GuruFocus | View source ↗ | GuruFocus | Oct 8, 2026 | neutral | 0 | 0.6 |
| Reasons to Retain Hims & Hers Stock in Your Portfolio for Now | Hims & Hers (HIMS) is accelerating growth through weight loss offerings, international expansion, and AI-enabled care, with U.S. revenues up 16% and international revenues surging 17-fold. However, the company faces headwinds from gross margin compression due to lower-margin branded products, negative cash flow from working capital requirements, and regulatory uncertainty around FDA peptide therapy approvals. The stock has gained 49.5% in six months but carries a Zacks Rank #3 (Hold) rating. | View source ↗ | Zacks Investment Research | Oct 8, 2026 | bullish | 0.25 | 1 |
| Reasons to Retain Hims & Hers Stock in Your Portfolio for Now | Hims & Hers (HIMS) is accelerating growth through weight loss offerings, international expansion, and AI-enabled care, with U.S. revenues up 16% and international revenues surging 17-fold. However, the company faces headwinds from gross margin compression due to lower-margin branded products, negative cash flow from working capital requirements, and regulatory uncertainty around FDA peptide therapy approvals. The stock has gained 49.5% in six months but carries a Zacks Rank #3 (Hold) rating. | View source ↗ | Zacks Investment Research | Oct 8, 2026 | bullish | 0.25 | 1 |
| 10x Genomics & Fred Hutch Join Forces on Cancer Biomarker Research | 10x Genomics announced a multi-project research collaboration with Fred Hutchinson Cancer Center to advance single-cell and spatial technologies for biomarker discovery in bladder cancer and residual disease detection in acute myeloid leukemia. The company will utilize its Flex Apex and Xenium platforms to identify treatment response markers. Despite the strategic partnership, TXG stock declined 5.6% following the announcement, though it has gained 366.6% year-to-date. | View source ↗ | Zacks Investment Research | Oct 8, 2026 | bullish | 1 | 1 |
| 10x Genomics & Fred Hutch Join Forces on Cancer Biomarker Research | 10x Genomics announced a multi-project research collaboration with Fred Hutchinson Cancer Center to advance single-cell and spatial technologies for biomarker discovery in bladder cancer and residual disease detection in acute myeloid leukemia. The company will utilize its Flex Apex and Xenium platforms to identify treatment response markers. Despite the strategic partnership, TXG stock declined 5.6% following the announcement, though it has gained 366.6% year-to-date. | View source ↗ | Zacks Investment Research | Oct 8, 2026 | bullish | 1 | 1 |
| 10x Genomics & Fred Hutch Join Forces on Cancer Biomarker Research | 10x Genomics announced a multi-project research collaboration with Fred Hutchinson Cancer Center to advance single-cell and spatial technologies for biomarker discovery in bladder cancer and residual disease detection in acute myeloid leukemia. The company will utilize its Flex Apex and Xenium platforms to identify treatment response markers. Despite the strategic partnership, TXG stock declined 5.6% following the announcement, though it has gained 366.6% year-to-date. | View source ↗ | Zacks Investment Research | Oct 8, 2026 | bullish | 1 | 1 |
| Merit Medical Systems, Inc. (MMSI) Stock Forecasts - Yahoo Finance | Merit Medical Systems, Inc. (MMSI) Stock Forecasts Yahoo Finance | View source ↗ | Yahoo Finance | Oct 8, 2026 | neutral | 0 | 0.6 |
| Reasons to Retain Fresenius Medical Stock in Your Portfolio for Now | Fresenius Medical Care (FMS) is improving profitability through its FME25+ transformation program and showing promise with 5008X dialysis system adoption and value-based care expansion. However, the company faces significant headwinds including U.S. treatment volume weakness, TDAPA reimbursement reversals expected to create a €50 million headwind in 2026, China regulatory pressure, and inflation concerns. The company maintains a Zacks Rank #3 (Hold) rating with consensus expectations for 2.7% revenue growth but 5.4% earnings decline in 2026. | View source ↗ | Zacks Investment Research | Oct 7, 2026 | bullish | 0.75 | 1 |
| A 4:30 p.m. Eastern investor call is planned for Oct. 29, when Merit Medical releases third-quarter results. - Stock Titan | A 4:30 p.m. Eastern investor call is planned for Oct. 29, when Merit Medical releases third-quarter results. Stock Titan | View source ↗ | Stock Titan | Oct 6, 2026 | neutral | 0 | 0.6 |
| HSIC or MMSI: Which Is the Better Value Stock Right Now? | In a comparison of two Medical-Dental Supplies stocks, Henry Schein (HSIC) and Merit Medical (MMSI), both holding a Zacks Rank #2 (Buy), HSIC emerges as the superior value opportunity. HSIC has a lower forward P/E ratio of 15.72 compared to MMSI's 20.29, a better PEG ratio of 1.49 versus 1.94, and a lower P/B ratio of 2.46 versus 3.1. HSIC received a Value grade of A while MMSI received a C grade. | View source ↗ | Zacks Investment Research | Oct 6, 2026 | bullish | 0.5 | 1 |
| HSIC or MMSI: Which Is the Better Value Stock Right Now? | In a comparison of two Medical-Dental Supplies stocks, Henry Schein (HSIC) and Merit Medical (MMSI), both holding a Zacks Rank #2 (Buy), HSIC emerges as the superior value opportunity. HSIC has a lower forward P/E ratio of 15.72 compared to MMSI's 20.29, a better PEG ratio of 1.49 versus 1.94, and a lower P/B ratio of 2.46 versus 3.1. HSIC received a Value grade of A while MMSI received a C grade. | View source ↗ | Zacks Investment Research | Oct 6, 2026 | bullish | 0.5 | 1 |
| HSIC or MMSI: Which Is the Better Value Stock Right Now? - Yahoo Finance | HSIC or MMSI: Which Is the Better Value Stock Right Now? Yahoo Finance | View source ↗ | Yahoo Finance | Oct 6, 2026 | neutral | 0 | 0.6 |
| Here's Why You Should Add Merit Medical Stock to Your Portfolio Now - TradingView | Here's Why You Should Add Merit Medical Stock to Your Portfolio Now TradingView | View source ↗ | TradingView | Oct 6, 2026 | neutral | 0 | 0.6 |
| Reasons to Retain Cardinal Health Stock in Your Portfolio for Now | Cardinal Health (CAH) expects Pharma profit growth of 8-11% in fiscal 2027 despite normalized demand, with other businesses projected to grow 15-18%. The company benefits from strong operational efficiency and specialty pharmaceutical growth, but faces headwinds from IRA pricing changes, moderating Specialty growth, and commodity cost pressures in its GMPD segment. | View source ↗ | Zacks Investment Research | Oct 6, 2026 | bullish | 0.75 | 1 |
| Reasons to Retain Cardinal Health Stock in Your Portfolio for Now | Cardinal Health (CAH) expects Pharma profit growth of 8-11% in fiscal 2027 despite normalized demand, with other businesses projected to grow 15-18%. The company benefits from strong operational efficiency and specialty pharmaceutical growth, but faces headwinds from IRA pricing changes, moderating Specialty growth, and commodity cost pressures in its GMPD segment. | View source ↗ | Zacks Investment Research | Oct 6, 2026 | bullish | 0.75 | 1 |
| Zacks Industry Outlook Highlights McKesson, Cardinal Health, Becton, Dickinson, Merit Medical Systems and ProDex | The Medical-Dental Supplies industry is positioned for growth driven by specialty care, biologics, GLP-1 therapies, and technology adoption, with the global market expected to reach $318.77 billion by 2031. However, tariffs, commodity inflation, and policy-driven pricing changes present headwinds. Five key stocks—McKesson, Cardinal Health, Becton Dickinson, Merit Medical Systems, and ProDex—are highlighted as well-positioned to capitalize on favorable industry trends through 2026. | View source ↗ | Zacks Investment Research | Oct 2, 2026 | bullish | 0.8 | 1 |
| Zacks Industry Outlook Highlights McKesson, Cardinal Health, Becton, Dickinson, Merit Medical Systems and ProDex | The Medical-Dental Supplies industry is positioned for growth driven by specialty care, biologics, GLP-1 therapies, and technology adoption, with the global market expected to reach $318.77 billion by 2031. However, tariffs, commodity inflation, and policy-driven pricing changes present headwinds. Five key stocks—McKesson, Cardinal Health, Becton Dickinson, Merit Medical Systems, and ProDex—are highlighted as well-positioned to capitalize on favorable industry trends through 2026. | View source ↗ | Zacks Investment Research | Oct 2, 2026 | bullish | 0.8 | 1 |
| Merit Medical Systems (NasdaqGS:MMSI) Stock Forecast & Analyst Predictions - Simply Wall Street | Merit Medical Systems (NasdaqGS:MMSI) Stock Forecast & Analyst Predictions Simply Wall Street | View source ↗ | Simply Wall Street | Oct 2, 2026 | neutral | 0 | 0.6 |
| 5 Medical Dental Supply Stocks to Watch as Industry Prospects Improve | The Medical-Dental Supplies industry is positioned for growth driven by specialty care, biologics, GLP-1 therapies, AI automation, and aging demographics. The global medical supplies market is expected to reach $318.77 billion by 2031 with a 10% CAGR. However, tariffs, commodity inflation, and pharmaceutical pricing changes remain headwinds. Key industry players show mixed near-term prospects with the industry trading at favorable valuations compared to broader markets. | View source ↗ | Zacks Investment Research | Oct 1, 2026 | bullish | 0.6 | 1 |
| 5 Medical Dental Supply Stocks to Watch as Industry Prospects Improve | The Medical-Dental Supplies industry is positioned for growth driven by specialty care, biologics, GLP-1 therapies, AI automation, and aging demographics. The global medical supplies market is expected to reach $318.77 billion by 2031 with a 10% CAGR. However, tariffs, commodity inflation, and pharmaceutical pricing changes remain headwinds. Key industry players show mixed near-term prospects with the industry trading at favorable valuations compared to broader markets. | View source ↗ | Zacks Investment Research | Oct 1, 2026 | bullish | 0.6 | 1 |
| Merit Medical Systems, Inc. (MMSI) Stock Forecasts - Yahoo Finance | Merit Medical Systems, Inc. (MMSI) Stock Forecasts Yahoo Finance | View source ↗ | Yahoo Finance | Oct 1, 2026 | neutral | 0 | 0.6 |
| 2 Reasons to Sell MMSI and 1 Stock to Buy Instead - Yahoo Finance | 2 Reasons to Sell MMSI and 1 Stock to Buy Instead Yahoo Finance | View source ↗ | Yahoo Finance | Sep 21, 2026 | neutral | 0 | 0.6 |
| 2 Reasons to Sell MMSI and 1 Stock to Buy Instead - StockStory | 2 Reasons to Sell MMSI and 1 Stock to Buy Instead StockStory | View source ↗ | StockStory | Sep 20, 2026 | neutral | 0 | 0.6 |
| Insider Sale: CHIEF OPERATING OFFICER of $MMSI Sells 7,500 Shares | MMSI Stock News - Quiver Quantitative | Insider Sale: CHIEF OPERATING OFFICER of $MMSI Sells 7,500 Shares | MMSI Stock News Quiver Quantitative | View source ↗ | Quiver Quantitative | Aug 25, 2026 | neutral | 0 | 0.6 |
| Merit Medical Systems Stock Climbs 25% On A 14-Day Winning Streak - Trefis | Merit Medical Systems Stock Climbs 25% On A 14-Day Winning Streak Trefis | View source ↗ | Trefis | Aug 13, 2026 | neutral | 0 | 0.6 |
| Merit Medical Systems (NASDAQ:MMSI) Reports Bullish Q2 CY2026, Stock Soars - StockStory | Merit Medical Systems (NASDAQ:MMSI) Reports Bullish Q2 CY2026, Stock Soars StockStory | View source ↗ | StockStory | Jul 30, 2026 | neutral | 0 | 0.6 |
| Here's Why You Should Add Merit Medical Stock to Your Portfolio Now - Yahoo Finance | Here's Why You Should Add Merit Medical Stock to Your Portfolio Now Yahoo Finance | View source ↗ | Yahoo Finance | Jul 9, 2026 | neutral | 0 | 0.6 |
Informational research only, not financial advice. Forecasts are uncertain and can be wrong.